In recent years, the NOACs, such as dabigatran (DTI), and rivaroxaban, apixaban, and edoxaban (direct Factor Xa inhibitors), have been approved for primary and secondary prevention of stroke in patients with nonvalvular AF. The gene discussed is F10; the disease is Stroke.